Carfilzomib, a proteasome inhibitor, is indicated for the treatment of patients with multiple myeloma. Multiple myeloma (multiple myeloma, MM) is a malignant tumor originating from the B cell lineage, characterized by the clonal proliferation of malignant plasma cells in the bone ...Learn More

According to the latest IDF Diabetes map, the global prevalence of diabetes reached 10.5% in 2021, with 537 million adults living with diabetes. China has become a disaster zone for diabetes, with the largest number of adults with diabetes in the world. In the past 10 years ...Learn More

Although the treatment of type 2 diabetes (T2DM) has made impressive progress in the past few decades, researchers are constantly searching for new treatments. How to better control blood glucose and reduce diabetes-related complications has become a hot topic in the field of T2DM ...Learn More

Alzheimer's disease (AD) is a progressive, irreversible neurodegenerative disease clinically manifested by cognitive impairment, behavioral abnormalities, and social deficits. It is predicted that by 2050, the number of people 65 and older with dementia in the United States could ...Learn More

Canagliflozin is a medication used to treat type 2 diabetes. It is a third-line medication to be tried after metformin, a first-line medication for type 2 diabetes. It is used together with exercise and diet. It is not recommended in type 1 diabetes. Mechanism action of ...Learn More